Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
瑋俊生物科技有限公司
Wai Chun Bio-Technology Limited
(Incorporated in the Cayman Islands with limited liabilities)
(Stock Code: 0660)
CHANGE OF AUDITOR
This announcement is made by Wai Chun Bio-Technology Limited (the "Company") pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
RESIGNATION OF AUDITOR
The board (the "Board") of directors (the "Directors") of the Company announces that HLM CPA Limited ("HLM") has resigned as the auditor of the Company with effect from 25 February 2021, as the Company and HLM could not reach a consensus on the audit fee for the financial year ended 31 December 2020.
The Company has received a confirmation from HLM that save for the disclosures under the heading "Material Uncertainty Related to Going Concern" in its audit report dated 23 June 2020 on the consolidated financial statements of the Company for the year ended 31 December 2019, there are no matters which HLM needs to bring to the attention of the shareholders of the Company (the "Shareholders") in relation to its resignation as auditor of the Company. The Board has also confirmed that there is no disagreement between HLM and the Company, and there is no matter in respect of the resignation of HLM that need to be brought to the attention of the Shareholders.
The Board would like to express its appreciation to HLM for their services rendered to the Company in the past years.
APPOINTMENT OF AUDITOR
In accordance with the articles of association of the Company, the Board, with the recommendation of the audit committee of the Company, has resolved to appoint Zhonghui Anda CPA Limited as the auditor of the Company with effect from 25 February 2021 to fill the casual vacancy following the resignation of HLM and to hold office until the conclusion of the next annual general meeting of the Company.
By order of the Board
Wai Chun Bio-Technology Limited
LAM Ching Kui Chairman and Chief Executive Officer
Hong Kong, 25 February 2021
As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ching Kui (Chairman and Chief Executive Officer) and three independent non-executive Directors, namely Mr. Chan Cheuk Ho, Mr. Wan Bo and Mr. Hau Pak Man.